Cardiol Therapeutics (CRDL) Total Current Liabilities (2020 - 2026)

Cardiol Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• Quarterly Total Current Liabilities fell 3.79% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 3.79% YoY) and the FY2025 annual result came in at $4.1 million, down 19.19% from the prior year.
• Total Current Liabilities was $5.2 million for Q1 2026 at Cardiol Therapeutics, up from $4.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $8.9 million in Q2 2022 and bottomed at $2.4 million in Q3 2025.
• A 5-year average of $6.1 million and a median of $6.0 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 274.35% — and 2025, when it plunged 53.11%.
• Cardiol Therapeutics' Total Current Liabilities stood at $7.2 million in 2022, then declined by 15.64% to $6.1 million in 2023, then declined by 17.65% to $5.0 million in 2024, then slipped by 19.19% to $4.1 million in 2025, then increased by 28.15% to $5.2 million in 2026.
• Business Quant data shows CRDL's Total Current Liabilities at $5.2 million in Q1 2026, $4.1 million in Q4 2025, and $2.4 million in Q3 2025.